Laurion Capital Management LP Bluebird Bio, Inc. Transaction History

Laurion Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.94 - $5.23 $29,793 - $53,000	10,134 New	10,134 $42,000
Q3 2019 Nov 13, 2019	SELL	$59.47 - $93.1 $914,113 - $1.43 Million	-15,371 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$75.84 - $105.21 $1.17 Million - $1.62 Million	15,371 New	15,371 $1.96 Million
Q1 2019 May 08, 2019	SELL	$64.44 - $104.11 $884,761 - $1.43 Million	-13,730 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $5.28 Million - $8.33 Million	-89,308 Reduced 86.67%	13,730 $1.36 Million
Q3 2018 Nov 13, 2018	BUY	$88.86 - $117.49 $9.16 Million - $12.1 Million	103,038 New	103,038 $15 Million
Q1 2018 May 14, 2018	SELL	$105.8 - $150.94 $15.5 Million - $22.1 Million	-146,127 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$81.25 - $130.7 $11.9 Million - $19.1 Million	146,127	146,127 $26 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.